Reduction of Adverse Drug Events and Readmissions

Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects

NCT02392702 ·Status: COMPLETED ·Phase: PHASE1

Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury

NCT06547229 ·Status: ACTIVE_NOT_RECRUITING

A Two-part Pharmacokinetic Study of PXS-5382A in Healthy Adult Males

NCT04183517 ·Status: COMPLETED ·Phase: PHASE1

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

NCT04097704 ·Status: COMPLETED

A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

NCT04207957 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038 ·Status: COMPLETED ·Phase: PHASE1

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

NCT04091061 ·Status: COMPLETED ·Phase: PHASE1

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

NCT02975388 ·Status: COMPLETED ·Phase: PHASE1

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

NCT06576765 ·Status: COMPLETED ·Phase: PHASE1

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

NCT00692341 ·Status: COMPLETED ·Phase: PHASE1

Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects

NCT01124279 ·Status: COMPLETED ·Phase: PHASE1

A Study of JNJ-64281802 in Healthy Adult Participants

NCT05201937 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

NCT04237831 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of Inhaled Levosimendan

NCT06387862 ·Status: RECRUITING ·Phase: PHASE2

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers

NCT01043094 ·Status: COMPLETED ·Phase: PHASE4

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479 ·Status: COMPLETED ·Phase: PHASE1

A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers

NCT05830799 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects

NCT01405599 ·Status: COMPLETED ·Phase: PHASE1

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

NCT01141179 ·Status: COMPLETED ·Phase: PHASE1

Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

NCT02154022 ·Status: ENROLLING_BY_INVITATION

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

NCT05718258 ·Status: COMPLETED ·Phase: PHASE1

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

NCT02621047 ·Status: COMPLETED ·Phase: PHASE1

A Retrospective Study on Drug Induced Liver Injury in China

NCT02407964 ·Status: COMPLETED

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

NCT03562117 ·Status: COMPLETED ·Phase: PHASE1